Skip to main content

20-10-2015 | Genitourinary cancers | Article

Immune checkpoint inhibitors: a new frontier in bladder cancer

World Journal of Urology

Authors: Max Kates, Nikolai A. Sopko, Hotaka Matsui, Charles G. Drake, Noah M. Hahn, Trinity J. Bivalacqua

Publisher: Springer Berlin Heidelberg


Immunotherapy is rapidly changing the field of urologic oncology. In this review, we discuss the role of the immune system in general and place a particular emphasis on the biology of the immune checkpoint and its role in cancer. Bladder cancer, as one of the most immunogenic neoplasms, is an exciting target for immune checkpoint inhibition. Early preclinical data and human trial experience suggest that this new drug class may shape bladder cancer therapy for years to come.

Please log in to get access to this content

Related topics